BioHermes Bio & Medical Technology
Wuxi, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese diagnostics company focused on point-of-care HbA1c analyzers for diabetes management, with FDA-cleared products and global market presence.
Metabolic
Technology Platform
Boronate affinity chromatography for glycated hemoglobin (HbA1c) measurement, enabling rapid, accurate diabetes monitoring in both point-of-care and laboratory settings.
Opportunities
Expansion into emerging markets with high diabetes prevalence and limited laboratory infrastructure, plus diversification into broader chronic disease testing through their immunofluorescence platform.
Risk Factors
Intense competition from global diagnostics giants, potential regulatory hurdles in Western markets for Chinese medical devices, and reliance on a primarily single-marker (HbA1c) product portfolio.
Competitive Landscape
Competes against Abbott (Afion), Roche (Cobas), and Siemens (DCA Vantage) in HbA1c testing, but differentiates through cost-effective point-of-care solutions and being the first Chinese company with FDA clearance in this category.